Treatment of Severe Atopic Dermatitis Patients with Cyclosporin A(CyA): the Long-Term Safety and Efficacy.

1999 ◽  
Vol 61 (3) ◽  
pp. 271-278
Author(s):  
Yumiko KUBOTA ◽  
Shuhei IMAYAMA ◽  
Hiroko MIYAHARA ◽  
Tomoko TANAHASHI ◽  
Yoko UEMURA ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Cyclosporin A ◽  
Severe Atopic Dermatitis ◽  
Safety And Efficacy

scholarly journals Dupilumab Provides Acceptable Long-Term Safety and Efficacy in Children Aged ≥ 6 to < 12 Years with Uncontrolled, Severe Atopic Dermatitis

2020 ◽  
Vol 4 (6) ◽  
pp. s104
Author(s):  
Michael Cork ◽  
Diamant Thaçi ◽  
Lawrence Eichenfield ◽  
Peter Arkwright ◽  
Zhen Chen ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Severe Atopic Dermatitis ◽  
Safety And Efficacy

Abstract not available.

Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: A randomized controlled trial

2011 ◽  
Vol 64 (6) ◽  
pp. 1074-1084 ◽  
Author(s):  
Inge M. Haeck ◽  
Mirjam J. Knol ◽  
Onno ten Berge ◽  
Sara G.A. van Velsen ◽  
Marjolein S. de Bruin-Weller ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Atopic Dermatitis ◽  
Cyclosporin A ◽  
Controlled Trial ◽  
Term Treatment ◽  
Severe Atopic Dermatitis ◽  
Randomized Controlled ◽  
Long Term Treatment ◽  
Enteric Coated

scholarly journals Long-Term Safety and Efficacy of Open-Label Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis

2017 ◽  
Vol 139 (2) ◽  
pp. AB381 ◽  
Author(s):  
Mette Deleuran ◽  
Diamant Thaçi ◽  
Lisa A. Beck ◽  
Seth Forman ◽  
Weily Soong ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Severe Atopic Dermatitis ◽  
Open Label ◽  
Safety And Efficacy

scholarly journals Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study

2020 ◽  
Vol 82 (2) ◽  
pp. 377-388 ◽  
Author(s):  
Mette Deleuran ◽  
Diamant Thaçi ◽  
Lisa A. Beck ◽  
Marjolein de Bruin-Weller ◽  
Andrew Blauvelt ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Extension Study ◽  
Severe Atopic Dermatitis ◽  
Open Label ◽  
Phase 3 ◽  
Safety And Efficacy ◽  
Open Label Extension

scholarly journals Long‐term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis

2019 ◽  
Vol 47 (2) ◽  
pp. 114-120 ◽  
Author(s):  
Hidemi Nakagawa ◽  
Osamu Nemoto ◽  
Atsuyuki Igarashi ◽  
Hidehisa Saeki ◽  
Ryusei Murata ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Kinase Inhibitor ◽  
Janus Kinase ◽  
Adult Patients ◽  
Janus Kinase Inhibitor ◽  
Safety And Efficacy

scholarly journals 408 Long-term treatment with dupilumab minimizes use of systemic immunosuppressants as rescue medications in adults with moderate-to-severe atopic dermatitis

2020 ◽  
Vol 140 (7) ◽  
pp. S53
Author(s):  
L.A. Beck ◽  
A. Blauvelt ◽  
L. Sher ◽  
I. Hussain ◽  
A.B. Rossi ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Term Treatment ◽  
Severe Atopic Dermatitis ◽  
Long Term Treatment
Sign in / Sign up

Export Citation Format

Share Document